These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
202 related articles for article (PubMed ID: 32052367)
1. Androgenetic alopecia: effects of oral finasteride on hormone profile, reproduction and sexual function. Pallotti F; Senofonte G; Pelloni M; Cargnelutti F; Carlini T; Radicioni AF; Rossi A; Lenzi A; Paoli D; Lombardo F Endocrine; 2020 Jun; 68(3):688-694. PubMed ID: 32052367 [TBL] [Abstract][Full Text] [Related]
2. Immunohistochemical evaluation of androgen receptor and nerve structure density in human prepuce from patients with persistent sexual side effects after finasteride use for androgenetic alopecia. Di Loreto C; La Marra F; Mazzon G; Belgrano E; Trombetta C; Cauci S PLoS One; 2014; 9(6):e100237. PubMed ID: 24959691 [TBL] [Abstract][Full Text] [Related]
3. An observational retrospective evaluation of 79 young men with long-term adverse effects after use of finasteride against androgenetic alopecia. Chiriacò G; Cauci S; Mazzon G; Trombetta C Andrology; 2016 Mar; 4(2):245-50. PubMed ID: 26763726 [TBL] [Abstract][Full Text] [Related]
4. Evaluation of sexual function with an international index of erectile function in subjects taking finasteride for androgenetic alopecia. Tosti A; Pazzaglia M; Soli M; Rossi A; Rebora A; Atzori L; Barbareschi M; Benci M; Voudouris S; Vena GA Arch Dermatol; 2004 Jul; 140(7):857-8. PubMed ID: 15262698 [TBL] [Abstract][Full Text] [Related]
5. Evaluation of sexual function in subjects taking finasteride for the treatment of androgenetic alopecia. Tosti A; Piraccini BM; Soli M J Eur Acad Dermatol Venereol; 2001 Sep; 15(5):418-21. PubMed ID: 11763381 [TBL] [Abstract][Full Text] [Related]
6. Finasteride for androgenetic alopecia is not associated with sexual dysfunction: a survey-based, single-centre, controlled study. Haber RS; Gupta AK; Epstein E; Carviel JL; Foley KA J Eur Acad Dermatol Venereol; 2019 Jul; 33(7):1393-1397. PubMed ID: 30835851 [TBL] [Abstract][Full Text] [Related]
7. Controversies in the treatment of androgenetic alopecia: The history of finasteride. Andy G; John M; Mirna S; Rachita D; Michael K; Maja K; Aseem S; Zeljana B Dermatol Ther; 2019 Mar; 32(2):e12647. PubMed ID: 30253001 [TBL] [Abstract][Full Text] [Related]
8. Superiority of dutasteride over finasteride in hair regrowth and reversal of miniaturization in men with androgenetic alopecia: A randomized controlled open-label, evaluator-blinded study. Shanshanwal SJ; Dhurat RS Indian J Dermatol Venereol Leprol; 2017; 83(1):47-54. PubMed ID: 27549867 [TBL] [Abstract][Full Text] [Related]
9. Effect of dutasteride 0.5 mg/d in men with androgenetic alopecia recalcitrant to finasteride. Jung JY; Yeon JH; Choi JW; Kwon SH; Kim BJ; Youn SW; Park KC; Huh CH Int J Dermatol; 2014 Nov; 53(11):1351-7. PubMed ID: 24898559 [TBL] [Abstract][Full Text] [Related]
10. Adverse Sexual Effects of Treatment with Finasteride or Dutasteride for Male Androgenetic Alopecia: A Systematic Review and Meta-analysis. Lee S; Lee YB; Choe SJ; Lee WS Acta Derm Venereol; 2019 Jan; 99(1):12-17. PubMed ID: 30206635 [TBL] [Abstract][Full Text] [Related]
11. An open, randomized, comparative study of oral finasteride and 5% topical minoxidil in male androgenetic alopecia. Arca E; Açikgöz G; Taştan HB; Köse O; Kurumlu Z Dermatology; 2004; 209(2):117-25. PubMed ID: 15316165 [TBL] [Abstract][Full Text] [Related]
12. Comparitive effectiveness of finasteride vs Serenoa repens in male androgenetic alopecia: a two-year study. Rossi A; Mari E; Scarno M; Garelli V; Maxia C; Scali E; Iorio A; Carlesimo M Int J Immunopathol Pharmacol; 2012; 25(4):1167-73. PubMed ID: 23298508 [TBL] [Abstract][Full Text] [Related]
13. Androgenetic alopecia; drug safety and therapeutic strategies. Motofei IG; Rowland DL; Baconi DL; Tampa M; Sârbu MI; Păunică S; Constantin VD; Bălălău C; Păunică I; Georgescu SR Expert Opin Drug Saf; 2018 Apr; 17(4):407-412. PubMed ID: 29363345 [TBL] [Abstract][Full Text] [Related]
14. A pharmacogenetic survey of androgen receptor (CAG)n and (GGN)n polymorphisms in patients experiencing long term side effects after finasteride discontinuation. Cecchin E; De Mattia E; Mazzon G; Cauci S; Trombetta C; Toffoli G Int J Biol Markers; 2014 Dec; 29(4):e310-6. PubMed ID: 24855036 [TBL] [Abstract][Full Text] [Related]
15. Finasteride, 1 mg daily administration on male androgenetic alopecia in different age groups: 10-year follow-up. Rossi A; Cantisani C; Scarnò M; Trucchia A; Fortuna MC; Calvieri S Dermatol Ther; 2011; 24(4):455-61. PubMed ID: 21910805 [TBL] [Abstract][Full Text] [Related]
16. Persistent sexual side effects of finasteride for male pattern hair loss. Irwig MS; Kolukula S J Sex Med; 2011 Jun; 8(6):1747-53. PubMed ID: 21418145 [TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of finasteride therapy for androgenetic alopecia: a systematic review. Mella JM; Perret MC; Manzotti M; Catalano HN; Guyatt G Arch Dermatol; 2010 Oct; 146(10):1141-50. PubMed ID: 20956649 [TBL] [Abstract][Full Text] [Related]
18. Persistent sexual side effects of finasteride: could they be permanent? Irwig MS J Sex Med; 2012 Nov; 9(11):2927-32. PubMed ID: 22789024 [TBL] [Abstract][Full Text] [Related]
19. Therapeutic experience with oral finasteride for androgenetic alopecia in female-to-male transgender patients. Moreno-Arrones OM; Becerra A; Vano-Galvan S Clin Exp Dermatol; 2017 Oct; 42(7):743-748. PubMed ID: 28691187 [TBL] [Abstract][Full Text] [Related]
20. Finasteride in the treatment of Taiwanese men with androgenetic alopecia: a 12-month open-label study. Lin JH; Chen WC Kaohsiung J Med Sci; 2002 Aug; 18(8):379-85. PubMed ID: 12476680 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]